Should You Buy Skyward Specialty Insurance Group Inc (SKWD) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
Not a good buy right now. Despite strong fundamentals and very bullish Wall Street targets driven by the Apollo acquisition and specialty/E&S tailwinds, the stock’s near-term technical setup is bearish (SMA200 > SMA20 > SMA5, MACD below zero) and the pattern-based forecast also leans negative over the next day/week/month. For an impatient buyer who doesn’t want to wait for a cleaner entry, SKWD is a “hold / stay on the sidelines” today rather than a buy.
Technical Analysis
Price/Trend: SKWD is in a short-to-intermediate downtrend with bearish moving-average alignment (SMA_200 > SMA_20 > SMA_5), indicating rallies are more likely to be sold.
Momentum: MACD histogram is -0.0624 (below 0) and negatively contracting—bearish momentum is still present, though the contraction suggests downside momentum may be slowing.
RSI: RSI_6 at 39.754 is near the lower end of neutral, consistent with weak momentum but not an extreme oversold reversal signal.
Levels: Pivot 45.112 is just above the current price (~44.85). Near support: S1 43.836 then S2 43.048. Near resistance: R1 46.388 then R2 47.176. A decisive reclaim/hold above the pivot and then R1 would improve the near-term setup; failure risks a drift toward S1/S2.
Quant/Pattern read-through: Similar-candlestick analogs imply a 90% chance of -1.16% next day, -1.35% next week, and -2.72% next month—reinforces that the immediate entry timing is unfavorable.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Analyst Ratings and Price Target Trends
Recent trend: Clear upward bias—multiple firms raised price targets in Dec 2025 and early Jan 2026 and maintained bullish ratings.
Key updates: Barclays reinstated with Overweight and $63 (Jan 8, 2026). Keefe Bruyette reiterated Outperform and raised PT to $69 (Jan 6, 2026). Citizens JMP reiterated Outperform and raised PT to $80 (Dec 4, 2025). Piper Sandler reiterated Overweight and raised PT to $64 (Dec 4, 2025).
Wall Street pros: Accretive Apollo acquisition, attractive specialty mix, continued E&S tailwinds, and pro forma guidance implying upside.
Wall Street cons (implied): Integration/execution risk and a potentially softening P&C pricing environment.
Influential buying/selling: Hedge funds neutral; insiders neutral (no significant recent trends). Congress trading: no recent data available.
Wall Street analysts forecast SKWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKWD is 65.83 USD with a low forecast of 49 USD and a high forecast of 80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast SKWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKWD is 65.83 USD with a low forecast of 49 USD and a high forecast of 80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 45.150
Current: 45.150
